The recent criminal conviction of a former registered nurse due to a fatal medication error has shaken the healthcare foundation to its core. While this is not the first time a patient has been harmed from a wrong medication or wrong dose, this case sets a precedent that can potentially lead to a
ISMP Newsroom
Safe medication practices depend on communication within the healthcare community, including patients and their families. ISMP is at the forefront of medication error reporting and guidance on safe medication practices, and is often cited in the media as a reputable resource for current information and emerging trends. In 2020, ISMP formally affiliated with ECRI to create one of the largest quality and safety entities in the world. ISMP's Newsroom includes ISMP and ECRI news releases, as well as ISMP blog posts, statements, and other communications.
To schedule an interview or request to be added to ISMP’s news release distribution lists, contact Renee Brehio.
Recent Updates
ISMP will hold an invitational, virtual summit to discuss challenges and barriers to medication safety present in all types of perioperative settings and look to gain consensus on best practice adoption and implementation.
ISMP will hold an invitational, virtual sterile compounding safety summit to address safe practices related to the use of sterile compounding workflow software, automated compounding devices and robotic compounding automation.
Marcus Schabacker, President and CEO of ECRI and chair of the board of ISMP, speaks with Pharma's Almanac.
Chris will be recognized at the 51st Annual Assembly on October 28th and 29th at Valley Forge Casino Resort.
An international medication safety call to action is aimed at preventing fatalities due to medication errors with concentrated potassium injection, inadvertent intraspinal injection of vincristine, and accidental daily instead of weekly dosing of methotrexate in patients with psoriasis or rheumatoid arthritis.
The FDA monitors reports of adverse events and other problems with medical devices and alerts health professionals and the public when needed to ensure proper use of devices and the health and safety of patients.
Many serious patient illnesses and deaths linked to poor quality compounded drugs have occurred since the 2012 fungal meningitis outbreak. FDA issues compounding risk alerts to communicate information about certain adverse events.
A study led by ISMP senior scientist Thomas J. Moore and published in JAMA Internal Medicine estimates the costs of pivotal clinical trials that the FDA relies on to prove the benefits of new drugs.
Community pharmacies that have administered AHRQ’s Community Pharmacy Survey on Patient Safety Culture can submit their data to the database October 1 – October 23.
The letter is signed by the members of the National Patient Safety Collaborative (NPSC), which include ECRI Institute, the Institute for Healthcare Improvement (IHI), ISMP, and the Joint Commission.
List of recommendations created after a November 2017 stakeholder roundtable on minimizing the impact of drug shortages on patient care.
ASHP has announced a correction to the printed edition of the Handbook on Injectable Drugs, 19th edition, in the reconstitution instructions for intramuscular injection of cefepime.
Wolters Kluwer has issued a correction for the neonatal dosing instructions given in the Penicillin G (Parenteral/Aqueous) monograph in in the Pediatric and Neonatal Lexi-Drugs database as well as in the print publication Pediatric & Neonatal Dosage Handbook--20th, 21st, 22nd, and 23rd editions.
Wolters Kluwer has issued a correction for the Methylprednisolone Acetate Injection monograph in the Drug Facts & Comparisons database and in the print publication Drug Facts and Comparisons-- 2015 and 2016.
ASHP has issued a recall and correction notice for the publication NICU Primer for Pharmacists, to the typical glucose infusion rates that appear in Chapter 3.
ASHP has issued an important correction notice for the publication Demystifying Drug Dosing in Obese Patients Critical Care, to section for Ibutilide that appears in Chapter 4.
Caffeine powder is marketed as a “pick-me-up”, and young people and athletes sometimes use it to make inexpensive, homemade caffeinated drinks and foods. But use of this powder can result in serious harm, including death.